AGP Executive Report
Last update: 3 hours agoFDA & Peptide Safety: A Public Citizen investigation says the FDA has largely let the “peptide craze” spread, flagging retatrutide use outside clinical trials and linking the unapproved weight-loss drug to hospitalizations. Diabetes Drug Watch: Novo Nordisk’s CagriSema (cagrilintide + semaglutide) showed stronger weight and A1c results in phase 3 trials for type 2 diabetes, including people on insulin. Massachusetts Health Policy: Massachusetts opioid overdose deaths fell below 1,000 for the first year since 2013, while MassHealth moves to end a homeless health care program serving thousands statewide. Workforce & Care Access: A federal judge in Boston struck down Trump’s $100,000 H-1B fee as an unlawful tax, a ruling that states say could otherwise raise costs for universities and healthcare training. Public Health Alerts: Health officials warned of rising norovirus in Boston-area facilities tied to summer cruise season and restaurant/camp exposures. Local Health & Community: Dana-Farber received a historic $50M Yawkey Foundation grant, supporting cancer care and research.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.